NASDAQ:KLRA

Kailera Therapeutics Q2 2026 Earnings Results & Report

Kailera Therapeutics logo
$12.20 -0.37 (-2.94%)
As of 04:00 PM Eastern

Kailera Therapeutics missed analyst earnings expectations in its Q2 2026 results, released August 12, 2026. The company reported EPS of -$1.09 versus the -$0.74 consensus estimate.

Earnings Announcement Details

Quarter
Q2 2026
Report Date
Time
After Market Closes
Conference Call
4:00 PM ET

Kailera Therapeutics EPS Results

Actual EPS
-$1.09
Consensus EPS
-$0.74
Beat/Miss
Missed by -$0.35
One Year Ago EPS
N/A

Kailera Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Kailera Therapeutics Q2 2026 Earnings FAQ

Kailera Therapeutics (NASDAQ:KLRA) reported earnings of -$1.09 per share for Q2 2026, missing the consensus estimate of -$0.74. The report was announced on Wednesday, August 12, 2026.

Kailera Therapeutics Earnings Headlines

Kailera Therapeutics to Present at ObesityWeek 2026
My public warning after 55 years of watching the markets
Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each warning issued before the crisis hit. Now the founder of Weiss Ratings, the only conflict-free rating agency in America, says he is watching a $3 trillion problem that could trigger a chain reaction across markets and banks.tc pixel
See More Kailera Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Kailera Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Kailera Therapeutics and other key companies, straight to your email.

About Kailera Therapeutics

Kailera Therapeutics (NASDAQ:KLRA) is a clinical-stage biopharmaceutical company developing medicines for obesity and related metabolic diseases. Its research focuses on treatments that act on biological pathways involved in appetite, weight regulation and metabolism.

The company’s pipeline includes investigational injectable and oral therapies, including programs designed to target GLP-1 and GIP receptors. These products are in development and are not approved for commercial use.

Founded in 2024, Kailera has secured development and commercialization rights outside Greater China to drug candidates discovered by Jiangsu Hengrui Pharmaceuticals. The company is based in Watertown, Massachusetts, and is led by President and Chief Executive Officer Ron Renaud.

View Kailera Therapeutics Profile